Recent Updates
Recently added Catalysts

Interpace Biosciences, Inc.

IDXGFDA catalysts, PDUFA dates & pipeline intelligence
$6.2
▲ +0.15 · +2.48%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full IDXG financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
Volume
1.43 K
Value Traded
8.78 K
Short % Float
-
Days to Cover
1.0
-6.06%Week

Cash Data

Unlock IDXG cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
34.35 M
EPS (TTM)
4.41
P/E Ratio
1.41
Ent. Value
31.66 M
Total Shares
5.54 M
Float Shares
-
Insiders
-
Institutions
-

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every IDXG catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

IDXG Catalyst Timeline

Dated clinical, regulatory and corporate events for Interpace Biosciences, Inc.

Unlock the full IDXG catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How IDXG actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all IDXG historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Interpace Biosciences, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every IDXG program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every IDXG trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock IDXG insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Burnell Thomas W.Director, Officer (CEO, President & Chairman)Option 1,966,763 2,037,645 held$0.00 08/20/2026
Unlock the full IDXG insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
No hedge fund reported a 13F position in IDXG for Q2 2026.
Unlock every fund holding IDXG
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in IDXG
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see IDXG ownership
Insider and institutional ownership, quarter by quarter.

IDXG Short Interest

Shares sold short, counted twice a month.

-
Short % of Float
of tradable shares sold short
13
Shares Sold Short
+550.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
4.2K
Avg Daily Volume
the average used for days to cover
Unlock IDXG short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock IDXG option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live IDXG option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock IDXG options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How IDXG ranks across every disease it competes in

Competitive Position is a premium feature
See how IDXG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

IDXG News

-IDXG
Nov 16, 2026
IDXGGeneral
▲ +2.5%today

Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results

Interpace Biosciences reported Q3 2026 revenue of $10.4 million, an 18% increase from the previous year. Despite a loss from continuing operations of $1.5 million, the company achieved a gross margin of 69% and an Adjusted EBITDA of $2.1 million. The results reflect ongoing operational improvements and a focus on thyroid diagnostics.

Read more →
-IDXG
Oct 15, 2026
IDXGGeneral

Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue

Interpace Biosciences anticipates preliminary, unaudited revenue for Q3 2026 to be between $10.1 million and $10.4 million. This represents an 11% to 14% increase from Q2 2026 and a 15% to 18% increase compared to Q3 2025. The final results will be reported after the company's quarter-end closing procedures.

Read more →
-IDXG
Aug 26, 2026
IDXGGeneral
▼ -11.6%on this news

Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting

Interpace Biosciences announced a 1-for-5 reverse stock split effective August 27, 2026. This move aims to meet Nasdaq's minimum bid price requirement for uplisting. The company will reduce its outstanding shares from approximately 27.7 million to about 5.5 million. The CEO expressed optimism that this strategy will enhance growth and investor interest.

Read more →
-IDXG
Jan 21, 2026
IDXGGeneral

Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure

Interpace Biosciences reported preliminary 2025 thyroid testing revenue of $38-39 million, reflecting a 21% increase from the previous year. The company anticipates a 16% growth in 2026 revenue, totaling around $40 million. Additionally, all preferred stock has been converted to common stock, simplifying the capital structure as Interpace aims for a Nasdaq uplisting.

Read more →

About Interpace Biosciences, Inc.

BIOPHARMAWATCH ELITE
Trade the next IDXG catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime